Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab

被引：115
|
作者：
Barnett, Richard [1 ]
Barta, Valerie S. [1 ]
Jhaveri, Kenar D. [1 ]
机构：
[1] Hofstra Northwell Sch Med, Hempstead, NY 11549 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2017年 / 376卷 / 02期
关键词：
IPILIMUMAB; MELANOMA;
D O I：
10.1056/NEJMc1614298
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：191 / 192
页数：2
相关论文
共 50 条
  • [31] Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma
    Marmarelis, Melina E.
    Davis, Meredith R.
    Sethi, Nilay S.
    Krajewksi, Katherine M.
    McKay, Rana R.
    Choueiri, Toni K.
    Ott, Patrick A.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
  • [32] Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice
    Tjulandin, Sergey
    Demidov, Lev
    Moiseyenko, Vladimir
    Protsenko, Svetlana
    Semiglazova, Tatiana
    Odintsova, Svetlana
    Zukov, Ruslan
    Lazarev, Sergey
    Makarova, Yuliya
    Nechaeva, Marina
    Sakaeva, Dina
    Andreev, Aleksey
    Tarasova, Anna
    Fadeyeva, Natalya
    Shustova, Mariia
    Kuryshev, Ivan
    EUROPEAN JOURNAL OF CANCER, 2021, 149 : 222 - 232
  • [33] Peripheral immune mapping and multi-omics analysis in Pd-1 inhibitor-induced myocarditis
    Gao, Jie
    Wang, Yan
    Lu, Lina
    Ma, Mingyue
    Ling, JiaQian
    Sun, Lu
    Chen, Yuwen
    Liu, Fangming
    Yu, Yiyi
    Liu, Tianshu
    Wu, Duojiao
    JOURNAL OF LEUKOCYTE BIOLOGY, 2023, 114 (02) : 164 - 179
  • [34] PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
    Luo, Min
    Xia, Yuhui
    Wang, Fang
    Zhang, Hong
    Su, Danting
    Su, Chaoyue
    Yang, Chuan
    Wu, Shaocong
    An, Sainan
    Lin, Suxia
    Fu, Liwu
    ACTA PHARMACEUTICA SINICA B, 2021, 11 (10) : 3120 - 3133
  • [35] Exploring CT Texture Parameters as Predictive and Response Imaging Biomarkers of Survival in Patients With Metastatic Melanoma Treated With PD-1 Inhibitor Nivolumab: A Pilot Study Using a Delta-Radiomics Approach
    Guerrisi, Antonino
    Russillo, Michelangelo
    Loi, Emiliano
    Ganeshan, Balaji
    Ungania, Sara
    Desiderio, Flora
    Bruzzaniti, Vicente
    Falcone, Italia
    Renna, Davide
    Ferraresi, Virginia
    Caterino, Mauro
    Solivetti, Francesco Maria
    Cognetti, Francesco
    Morrone, Aldo
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [36] Phase II trial of multi-tyrosine kinase inhibitor ESK981 in combination with PD-1 inhibitor nivolumab in patients with metastatic castration-resistant prostate cancer
    Heath, Elisabeth I.
    Chen, Wei
    Choi, Jae E.
    Dobson, Kimberlee
    Smith, Melanie
    Maj, Tomasz
    Kryczek, Ilona
    Zou, Weiping
    Chinnaiyan, Arul M.
    Qiao, Yuanyuan
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (06) : 675 - 684
  • [37] PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse
    Zheng, Bingxin
    Ren, Tingting
    Huang, Yi
    Sun, Kunkun
    Wang, Shidong
    Bao, Xing
    Liu, Kuisheng
    Guo, Wei
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [38] Real-world data on PD-1 inhibitor therapy in metastatic melanoma
    Arheden, Anna
    Skalenius, Joanna
    Bjursten, Sara
    Stierner, Ulrika
    Ny, Lars
    Levin, Max
    Jespersen, Henrik
    ACTA ONCOLOGICA, 2019, 58 (07) : 962 - 966
  • [39] Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers
    Rajan, Arun
    Kim, Chul
    Heery, Christopher R.
    Guha, Udayan
    Gulley, James L.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (09) : 2219 - 2231
  • [40] Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway
    Wakabayashi, Grace
    Lee, Yu-Ching
    Luh, Frank
    Kuo, Chun-Nan
    Chang, Wei-Chiao
    Yen, Yun
    JOURNAL OF BIOMEDICAL SCIENCE, 2019, 26 (01)
12345